BR0209114A - Terapia de combinação usando agentes antiangiogênicos e tnfalfa - Google Patents

Terapia de combinação usando agentes antiangiogênicos e tnfalfa

Info

Publication number
BR0209114A
BR0209114A BR0209114-3A BR0209114A BR0209114A BR 0209114 A BR0209114 A BR 0209114A BR 0209114 A BR0209114 A BR 0209114A BR 0209114 A BR0209114 A BR 0209114A
Authority
BR
Brazil
Prior art keywords
agents
combination therapy
antiangiogenic agents
administration
tfalphal
Prior art date
Application number
BR0209114-3A
Other languages
English (en)
Inventor
Matthias Grell
Simon Goodman
Curzio Ruegg
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of BR0209114A publication Critical patent/BR0209114A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/217—IFN-gamma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

"TERAPIA DE COMBINAçãO USANDO AGENTES ANTIANGIOGêNICOS E TNFalfa". A presente invenção refere-se a uma terapia de combinação para o tratamento de metástases de tumores, compreendendo a administração de agentes antiangiogênicos e fator de necrose tumoral alfa (TNFa), opcionalmente juntos com outros agentes citotóxicos, tais como o interferon gama (IFN~ <SYM>~), ou agentes quimioterapêuticos, tais como os anticorpos anti-EGFR. O método e as composições farmacêuticas compreendendo os ditos agentes podem resultar em uma potenciação sinérgica do efeito de inibição da proliferação das células de tumor de cada agente terapêutico individual, produzindo um tratamento mais eficaz do que verificado por administração de um componente individual sozinho.
BR0209114-3A 2001-04-24 2002-04-18 Terapia de combinação usando agentes antiangiogênicos e tnfalfa BR0209114A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01109981 2001-04-24
PCT/EP2002/004298 WO2002085405A2 (en) 2001-04-24 2002-04-18 COMBINATION THERAPY USING ANTI-ANGIOGENIC AGENTS AND TNF$g(a)

Publications (1)

Publication Number Publication Date
BR0209114A true BR0209114A (pt) 2004-07-13

Family

ID=8177227

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0209114-3A BR0209114A (pt) 2001-04-24 2002-04-18 Terapia de combinação usando agentes antiangiogênicos e tnfalfa

Country Status (20)

Country Link
US (3) US20040136949A1 (pt)
EP (2) EP1381384B1 (pt)
JP (2) JP4660067B2 (pt)
KR (1) KR100861466B1 (pt)
CN (1) CN1247258C (pt)
AT (1) ATE510557T1 (pt)
AU (1) AU2002316855B2 (pt)
BR (1) BR0209114A (pt)
CA (1) CA2444821C (pt)
CZ (1) CZ20033119A3 (pt)
DK (1) DK1381384T3 (pt)
ES (1) ES2366775T3 (pt)
HU (1) HUP0303927A3 (pt)
MX (1) MXPA03009683A (pt)
PL (1) PL363311A1 (pt)
PT (1) PT1381384E (pt)
RU (1) RU2316337C2 (pt)
SK (1) SK14272003A3 (pt)
WO (1) WO2002085405A2 (pt)
ZA (1) ZA200309060B (pt)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1381384E (pt) * 2001-04-24 2011-09-01 Merck Patent Gmbh Terapia de combinação usando agentes anti-angiogénicos e tnfa
EP1460088A1 (en) 2003-03-21 2004-09-22 Biotest AG Humanized anti-CD4 antibody with immunosuppressive properties
ATE546157T1 (de) 2003-11-13 2012-03-15 Sutter West Bay Hospitals Anti-pecam-therapie zur unterdrückung von metastasen
WO2005089443A2 (en) * 2004-03-19 2005-09-29 The Penn State Research Foundation Combinatorial methods and compositions for treatment of melanoma
DK1819358T3 (da) * 2004-11-18 2014-10-27 Imclone Llc Antistoffer mod vaskulær endothel-vækstfaktor-receptor-1
CA2593964A1 (en) 2004-12-23 2006-06-29 Molmed Spa Conjugation product
WO2006074370A2 (en) * 2005-01-07 2006-07-13 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Agonists and antagonists of tnfrii/cd120b for treatment of immune-related diseases
US20110165150A1 (en) * 2006-01-18 2011-07-07 Merck Patent Gmbh Isolated organ perfusion combination therapy of cancer
BRPI0806596A2 (pt) * 2007-01-18 2013-07-23 Merck Patent Ges Mit Berchraenkter Haftung medicamento e terapia especÍfica usando-se ligantes de integrina para o tratamento de cÂncer
WO2008103301A2 (en) * 2007-02-16 2008-08-28 President And Fellows Of Harvard College Treatment of the eye using macrophages and/or agents able to affect blood vessel morphology
MX2010010026A (es) 2008-03-13 2011-03-21 Biotest Ag Agente para tratar enfermedad.
SG190627A1 (en) 2008-03-13 2013-06-28 Biotest Ag Agent for treating disease
US8293714B2 (en) * 2008-05-05 2012-10-23 Covx Technology Ireland, Ltd. Anti-angiogenic compounds
WO2009140661A1 (en) * 2008-05-16 2009-11-19 Corthera, Inc. Method of preventing premature delivery
FR2931677B1 (fr) * 2008-06-02 2010-08-20 Sanofi Aventis Association d'un agoniste partiel des recepteurs nicotiniques et d'un inhibiteur d'acetylcholinesterase, composition la contenant et son utilisation dans le traitement des troubles cognitifs
SG194362A1 (en) * 2008-09-29 2013-11-29 Biotest Ag Composition for treating disease
AU2009305893B2 (en) * 2008-10-23 2014-03-27 Steba Biotech S.A. RGD-containing peptidomimetics and uses thereof
GB0920944D0 (en) 2009-11-30 2010-01-13 Biotest Ag Agents for treating disease
JP5212849B2 (ja) 2010-01-14 2013-06-19 株式会社三和化学研究所 眼内血管新生及び／又は眼内血管透過性亢進を伴う疾患の予防又は治療のための医薬
WO2011103583A2 (en) * 2010-02-22 2011-08-25 University Of Chicago Methods and compositions related to anti-angiogenic peptides
WO2012054717A2 (en) * 2010-10-21 2012-04-26 The Johns Hopkins University Detecting and treating solid tumors through selective disruption of tumor vasculature
WO2012105610A1 (ja) 2011-02-02 2012-08-09 公立大学法人名古屋市立大学 眼内血管新生及び／又は眼内血管透過性亢進を伴う疾患の予防又は治療のための医薬
RU2530592C2 (ru) * 2012-07-20 2014-10-10 Федеральное государственное бюджетное учреждение науки Институт теоретической и экспериментальной биофизики Российской академии наук (ИТЭБ РАН) Способ подавления роста опухолей
CN111868237A (zh) 2017-10-05 2020-10-30 弗尔康医疗公司 P38抑制剂降低dux4表达的用途
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
CN112569358B (zh) * 2019-09-30 2022-06-28 上海生物制品研究所有限责任公司 培干扰素和原癌基因产物靶向抑制剂在协同抑制肿瘤中的应用

Family Cites Families (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4503035B1 (en) 1978-11-24 1996-03-19 Hoffmann La Roche Protein purification process and product
US4530901A (en) 1980-01-08 1985-07-23 Biogen N.V. Recombinant DNA molecules and their use in producing human interferon-like polypeptides
US4342566A (en) 1980-02-22 1982-08-03 Scripps Clinic & Research Foundation Solid phase anti-C3 assay for detection of immune complexes
US4474893A (en) 1981-07-01 1984-10-02 The University of Texas System Cancer Center Recombinant monoclonal antibodies
US4661111A (en) 1982-08-04 1987-04-28 La Jolla Cancer Research Foundation Polypeptide
US4614517A (en) 1982-08-04 1986-09-30 La Jolla Cancer Research Foundation Tetrapeptide
US4517686A (en) 1982-08-04 1985-05-21 La Jolla Cancer Research Foundation Polypeptide
US4792525A (en) 1982-08-04 1988-12-20 La Jolla Cancer Research Foundation Tetrapeptide
US4589881A (en) 1982-08-04 1986-05-20 La Jolla Cancer Research Foundation Polypeptide
US4578079A (en) 1982-08-04 1986-03-25 La Jolla Cancer Research Foundation Tetrapeptide
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4943533A (en) 1984-03-01 1990-07-24 The Regents Of The University Of California Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor
US5231176A (en) 1984-08-27 1993-07-27 Genentech, Inc. Distinct family DNA encoding of human leukocyte interferons
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4968603A (en) 1986-12-31 1990-11-06 The Regents Of The University Of California Determination of status in neoplastic disease
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
WO1989006692A1 (en) * 1988-01-12 1989-07-27 Genentech, Inc. Method of treating tumor cells by inhibiting growth factor receptor function
AU4128089A (en) 1988-09-15 1990-03-22 Rorer International (Overseas) Inc. Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
DE69029036T2 (de) 1989-06-29 1997-05-22 Medarex Inc Bispezifische reagenzien für die aids-therapie
WO1991003493A1 (en) 1989-08-29 1991-03-21 The University Of Southampton Bi-or trispecific (fab)3 or (fab)4 conjugates
US5196446A (en) 1990-04-16 1993-03-23 Yissum Research Development Company Of The Hebrew University Of Jerusalem Certain indole compounds which inhibit EGF receptor tyrosine kinase
DK0553244T4 (da) 1990-10-05 2005-08-01 Celldex Therapeutics Inc Målrettet immunostimulering med bispecifikke reagenser
CA2097060A1 (en) 1990-12-04 1992-06-05 Peter J. Curtis Bifunctional antibodies and method of preparing same
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
CZ333796A3 (cs) 1991-03-06 1998-06-17 MERCK Patent Gesellschaft mit beschränkter Haftung Chimérická monoklonální protilátka, expresní vektory a farmaceutický prostředek
US5480883A (en) 1991-05-10 1996-01-02 Rhone-Poulenc Rorer Pharmaceuticals Inc. Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
DK0590058T3 (da) 1991-06-14 2004-03-29 Genentech Inc Humaniseret heregulin-antistof
US5587458A (en) 1991-10-07 1996-12-24 Aronex Pharmaceuticals, Inc. Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof
JPH07501451A (ja) 1991-11-25 1995-02-16 エンゾン・インコーポレイテッド 多価抗原結合タンパク質
US5932448A (en) 1991-11-29 1999-08-03 Protein Design Labs., Inc. Bispecific antibody heterodimers
AU661533B2 (en) 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
EP1997894B1 (en) 1992-02-06 2011-03-30 Novartis Vaccines and Diagnostics, Inc. Biosynthetic binding protein for cancer marker
DK0672142T3 (da) 1992-12-04 2001-06-18 Medical Res Council Multivalente og multispecifikke bindingsproteiner samt fremstilling og anvendelse af disse
US5679683A (en) 1994-01-25 1997-10-21 Warner-Lambert Company Tricyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family
IL112746A (en) * 1994-03-02 1999-12-31 Lilly Co Eli Orally administrable pharmaceutical formulation comprising raloxifene hydrochoride
US5656655A (en) 1994-03-17 1997-08-12 Rhone-Poulenc Rorer Pharmaceuticals, Inc. Styryl-substituted heteroaryl compounds which inhibit EGF receptor tyrosine kinase
US5753230A (en) 1994-03-18 1998-05-19 The Scripps Research Institute Methods and compositions useful for inhibition of angiogenesis
US5741796A (en) 1994-05-27 1998-04-21 Merck & Co., Inc. Pyridyl and naphthyridyl compounds for inhibiting osteoclast-mediated bone resorption
EP0767792A4 (en) 1994-06-29 2002-11-20 Smithkline Beecham Corp VITRONECTIN RECEPTOR ANTAGONISTS
WO1996000574A1 (en) 1994-06-29 1996-01-11 Smithkline Beecham Corporation Vitronectin receptor antagonists
IT1271688B (it) 1994-08-04 1997-06-04 Menarini Ricerche Sud Spa Molecole ibride per il trattamento antitumorale loro preparazione e loro uso in composizioni farmaceutiche
EP0777657A1 (en) 1994-08-22 1997-06-11 Smithkline Beecham Corporation Bicyclic compounds
DE69531187T2 (de) 1994-12-20 2004-04-22 Merck Patent Gmbh Monoklonaler Antikörper gegen das Alpha-V-Integrin
WO1996026190A1 (en) 1995-02-22 1996-08-29 Smithkline Beecham Corporation Integrin receptor antagonists
US5780426A (en) 1995-06-07 1998-07-14 Ixsys, Incorporated Fivemer cyclic peptide inhibitors of diseases involving αv β3
ATE238996T1 (de) 1995-06-29 2003-05-15 Smithkline Beecham Corp Integrin-rezeptor-antagonisten
DE19534177A1 (de) 1995-09-15 1997-03-20 Merck Patent Gmbh Cyclische Adhäsionsinhibitoren
BR9611174A (pt) 1995-10-23 1999-09-14 Childrens Medical Center Proteína de endostatina isolada, e composições terapêuticas antiangiogénicas formadas com a mesma.
WO1997024119A1 (en) 1995-12-29 1997-07-10 Smithkline Beecham Corporation Vitronectin receptor antagonists
KR19990076877A (ko) 1995-12-29 1999-10-25 스티븐 베네티아너 비트로넥틴 수용체 길항제
IL125034A0 (en) 1995-12-29 1999-01-26 Smithkline Beecham Corp Vitronectin receptor antagonists
KR20000064710A (ko) 1996-03-20 2000-11-06 제넨테크, 인코포레이티드 인테그린, 특히 ανβ3 인테그린에 대하여 특이 활성을갖는 3환식 화합물, 그 제조방법 및 그 제조를 위한 중간체, 의약으로서의 그 용도 및 그를 포함한 약제 조성물
JP2000508319A (ja) 1996-04-10 2000-07-04 メルク エンド カンパニー インコーポレーテッド αｖβ３拮抗薬
US5925655A (en) 1996-04-10 1999-07-20 Merck & Co., Inc. αv β3 antagonists
WO1997041844A1 (en) 1996-05-09 1997-11-13 Alcon Laboratories, Inc. Combinations of angiostatic compounds
CZ383498A3 (cs) 1996-05-31 1999-05-12 The Scripps Research Institute Průmyslový výrobek, antagonista integrinu alfav beta3, farmaceutický přípravek s obsahem alfav beta3 antagonisty a způsob inhibice angiogeneze ve tkáni
US5981546A (en) 1996-08-29 1999-11-09 Merck & Co., Inc. Integrin antagonists
CA2263999A1 (en) 1996-08-29 1998-03-05 Merck & Co., Inc. Integrin antagonists
JP2001501951A (ja) 1996-10-07 2001-02-13 スミスクライン・ビーチャム・コーポレイション 骨形成刺激方法
EP0946165B1 (en) 1996-10-30 2003-04-09 Merck & Co., Inc. Integrin antagonists
AU717283B2 (en) 1996-10-30 2000-03-23 Merck & Co., Inc. Integrin antagonists
US5919792A (en) 1996-10-30 1999-07-06 Merck & Co., Inc. Integrin antagonists
AU5596298A (en) 1996-12-09 1998-07-03 Cor Therapeutics, Inc. Integrin antagonists
DE19653645A1 (de) 1996-12-20 1998-06-25 Hoechst Ag Vitronectin - Rezeptorantagonisten, deren Herstellung sowie deren Verwendung
DE19653646A1 (de) 1996-12-20 1998-06-25 Hoechst Ag Substituierte Purinderivate, Verfahren zu deren Herstellung, sie enthaltende Mittel und deren Verwendung
DE19653647A1 (de) 1996-12-20 1998-06-25 Hoechst Ag Vitronectin - Rezeptorantagonisten, deren Herstellung sowie deren Verwendung
CO4920232A1 (es) 1997-01-08 2000-05-29 Smithkline Beecham Corp Acidos aceticos dibenzo [a,d] cicloheptano con actividad antagonista del receptor de vitronectin
JP2001509176A (ja) 1997-01-17 2001-07-10 メルク エンド カンパニー インコーポレーテッド インテグリンアンタゴニスト
US6590079B2 (en) * 1997-01-30 2003-07-08 Ixsys, Incorporated Anti-αvβ3 recombinant human antibodies, nucleic acids encoding same
CA2284726A1 (en) * 1997-04-11 1998-10-22 G.D. Searle & Co. Antagonistic anti-avb3 integrin antibodies
ES2246069T3 (es) 1997-05-02 2006-02-01 Genentech, Inc. Procedimiento de preparacion de anticuerpos multiespecificos que tienen componentes comunes y multimericos.
WO1999005107A1 (en) 1997-07-25 1999-02-04 Smithkline Beecham Corporation Vitronectin receptor antagonist
WO1999006049A1 (en) 1997-08-04 1999-02-11 Smithkline Beecham Corporation Integrin receptor antagonists
WO1999011626A1 (en) 1997-09-04 1999-03-11 Smithkline Beecham Corporation Integrin receptor antagonists
PE122699A1 (es) 1997-09-19 2000-02-12 Smithkline Beecham Corp Antagonistas de receptores de vitronectina
FR2768734B1 (fr) 1997-09-24 2000-01-28 Roussel Uclaf Nouveaux composes tricycliques, leur procede de preparation et les intermediaires de ce procede, leur application a titre de medicaments et les compositions pharmaceutiques les renfermant
BR9813214A (pt) 1997-09-24 2000-08-29 Smithkline Beecham Corp Antagonista de receptor vitronectina
EP1017387A4 (en) 1997-09-24 2004-08-18 Smithkline Beecham Corp VITRONEECT RECEPTOR ANTAGONIST
FR2768736B1 (fr) 1997-09-24 2000-05-26 Roussel Uclaf Nouveaux composes tricycliques, leur procede de preparation et les intermediaires de ce procede, leur application a titre de medicaments et les compositions pharmaceutiques les renfermant
IL136314A0 (en) 1997-12-17 2001-05-20 Merck & Co Inc Integrin receptor antagonists
EA002822B1 (ru) 1997-12-17 2002-10-31 Мерк Энд Ко., Инк. Антагонисты рецептора интегрина
US6048861A (en) 1997-12-17 2000-04-11 Merck & Co., Inc. Integrin receptor antagonists
AU736026B2 (en) 1997-12-17 2001-07-26 Merck & Co., Inc. Integrin receptor antagonists
US6017926A (en) 1997-12-17 2000-01-25 Merck & Co., Inc. Integrin receptor antagonists
EP1044001B1 (en) 1997-12-17 2005-07-06 Merck & Co., Inc. Integrin receptor antagonists
CA2319160A1 (en) 1998-01-23 1999-07-29 Merck Patent Gesellschaft Mit Beschraenkter Haftung Monoclonal antibody anti .alpha.v-integrin and its use to inhibit .alpha.v.beta.6-integrin attachment to fibronectin
CA2338275A1 (en) 1998-07-29 2000-02-10 Merck & Co., Inc. Integrin receptor antagonists
WO2000009503A1 (en) 1998-08-13 2000-02-24 Merck & Co., Inc. Integrin receptor antagonists
US6235877B1 (en) * 1999-08-04 2001-05-22 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Peptido-mimetic compounds containing RGD sequence useful as integrin inhibitors
JP2002533387A (ja) 1998-12-23 2002-10-08 ジー．ディー．サール ＆ カンパニー 腫瘍治療の複合療法としてインテグリン拮抗物質と一つ以上の抗腫瘍剤を使用する方法
TR200103431T2 (tr) 1999-06-02 2002-06-21 Merck & Co.,Inc. Alfa V integrin reseptör antagonistleri.
KR20090126330A (ko) * 1999-08-27 2009-12-08 제넨테크, 인크. 항-ＥｒｂＢ2 항체 투여 치료 방법
PT1381384E (pt) * 2001-04-24 2011-09-01 Merck Patent Gmbh Terapia de combinação usando agentes anti-angiogénicos e tnfa

Also Published As

Publication number Publication date
RU2003132431A (ru) 2005-04-10
EP2292251A1 (en) 2011-03-09
CA2444821A1 (en) 2002-10-31
HUP0303927A2 (hu) 2004-03-01
RU2316337C2 (ru) 2008-02-10
EP1381384A2 (en) 2004-01-21
JP4660067B2 (ja) 2011-03-30
WO2002085405A2 (en) 2002-10-31
WO2002085405A3 (en) 2003-10-02
SK14272003A3 (sk) 2004-04-06
ES2366775T3 (es) 2011-10-25
CA2444821C (en) 2012-07-10
PL363311A1 (en) 2004-11-15
AU2002316855B2 (en) 2008-03-13
PT1381384E (pt) 2011-09-01
KR100861466B1 (ko) 2008-10-02
CN1505527A (zh) 2004-06-16
US20040136949A1 (en) 2004-07-15
JP2009256373A (ja) 2009-11-05
EP1381384B1 (en) 2011-05-25
CN1247258C (zh) 2006-03-29
ZA200309060B (en) 2005-02-21
MXPA03009683A (es) 2004-02-12
DK1381384T3 (da) 2011-07-25
CZ20033119A3 (cs) 2005-01-12
KR20040030595A (ko) 2004-04-09
JP2004529149A (ja) 2004-09-24
ATE510557T1 (de) 2011-06-15
JP5178663B2 (ja) 2013-04-10
US20090035270A1 (en) 2009-02-05
HUP0303927A3 (en) 2006-03-28
US20110177027A1 (en) 2011-07-21

Similar Documents

Publication Publication Date Title
BR0209114A (pt) Terapia de combinação usando agentes antiangiogênicos e tnfalfa
BR0209147A (pt) Terapia combinada que usa anticorpos anti-egfr e agentes anti-hormonais
IL267381A (en) A pharmaceutical preparation containing dextromethorphan and quinidine for the treatment of nervous disorders
FI974268A0 (fi) Flavanolignaanien käyttö lääkkeiden, joilla on lisääntymistä torjuvaa vaikutusta kohdussa, munasarjoissa ja rintarauhasessa, valmistamiseksi
BR0009647A (pt) Docetaxel em combinação com rhumab her2 para o tratamento de cânceres
TW200612987A (en) Combination treatment for non-hematologic malignancies
BR0209658A (pt) Derivados de 4-amino-5-fenil-7-1ciclobutil-pirrolo [2,3-d] pirimidina
BR0316050A (pt) Métodos de tratar, controlar ou prevenir um câncer especìfico e doença associada com angiogênese indesejada e de reduzir ou evitar um efeito adverso associado com a administração de um segundo ingrediente ativo e com terapia de radiação, terapia hormonal, terapia biológica, ou imunoterapia em um paciente sofrendo de um câncer especìfico, composição farmacêutica e kit
BR9911076A (pt) Uso de peg-ifn-alfa e ribavirina para o tratamento de hepatite c crÈnica
SG166775A1 (en) Combinations and modes of administration of therapeutic agents and combination therapy
NO20071426L (no) Kreft kombinasjonsbehandling omfattende AZD2171 og Imatinib
HK1071310A1 (en) Combination therapy for the treatment of cancer
IS6558A (is) Blandaðar sjúkdómsmeðferðir með æðaskaðandi virkni
BR0316057A (pt) Métodos de tratar, controlar ou prevenir um câncer especìfico e uma doença associada com angiogênese indesejada e de reduzir ou evitar um efeito adverso associado com a administração de um segundo ingrediente ativo e com a terapia de radiação, terapia hormonal, terapia biológica ou imunoterapia em um paciente sofrendo de um câncer especìfico, composição farmacêutica e kit
BRPI0409926A (pt) saposina c-dops: um agente antitumor
BRPI0413410A (pt) co-administração de um polissacarìdeo com um agente quimioterapêutico para o tratamento de cáncer
NO20064753L (no) Kombinasjonsterapi
DE60321175D1 (de) Dichloracetat in kombination mit kardioprotektiven oder hämodynamischen medikamenten
MX2019014166A (es) Composicion farmaceutica de caseinato de sodio y antineoplasicos para el tratamiento de cancer.
BRPI0407301A (pt) Uso de uma combinação, composição farmacêutica, kit, e, método para o tratamento de câncer em um animal de sangue quente tal como um ser humano

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A(S) 8A E 9A ANUIDADE(S)

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2103 DE 26/04/2011.